Edition:
United Kingdom

Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

8.84USD
6:21pm BST
Change (% chg)

$-0.06 (-0.67%)
Prev Close
$8.90
Open
$8.88
Day's High
$9.02
Day's Low
$8.81
Volume
52,132
Avg. Vol
333,159
52-wk High
$34.45
52-wk Low
$6.99

Select another date:

Mon, Mar 5 2018

Dermira to abandon acne drug, shares crater

Dermira Inc will discontinue development of its acne drug after the treatment failed to meet the main goals of two late-stage studies, the company said on Monday.

UPDATE 2-Dermira to abandon acne drug, shares crater

* Drug results not to affect two other programs - company (Adds conference call details, analyst comment, updates share price)

Dermira abandons acne drug

March 5 Dermira Inc said on Monday it would discontinue the development of its acne drug after it failed to meet the main goals of two late-stage studies.

BRIEF-Dermira's Two Phase 3 Trials Evaluating Olumacostat Glasaretil In Patients With Acne Vulgaris Did Not Meet Co-Primary Endpoints

* DERMIRA’S TWO PHASE 3 TRIALS EVALUATING OLUMACOSTAT GLASARETIL IN PATIENTS WITH ACNE VULGARIS DID NOT MEET CO-PRIMARY ENDPOINTS

BRIEF-Dermira Qtrly Loss Per Share $‍1.34​

* DERMIRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Dermira posts Q3 loss $4.30/shr, says FDA accepts NDA for glycopyrronium tosylate

* Dermira reports third quarter 2017 financial results and announces that FDA accepts new drug application for glycopyrronium tosylate for the treatment of patients with primary axillary hyperhidrosis

BRIEF-Dermira and UCB agree to end collaboration agreement for Cimzia

* Dermira and UCB agree to end collaboration agreement for Cimzia

Select another date: